Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1869-1880

  Beuten, Joke ^a   Gelfond, Jonathan A L ^b   Franke, Jennifer L ^a   Weldon, Korri S ^a   Crandall, AnaLisa C ^a   Johnson Pais, Teresa L ^a   Thompson, Ian M ^a   Leach, Robin J ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CYTOCHROME P450; CYTOCHROME P450 24A1; STEROID HORMONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID METABOLISM;

AGED; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 67449085159     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0076     Document Type: Article

References (57)

1. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13 Spec No 1:R103-21. (Pubitemid 38443804)
2. Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev 2001;23:24-29 (Pubitemid 32906610)
3. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001;23:42-58.
4. Cheng E, Lee C, Grayhack J. Endocrinology of the prostate. In: Lepor H, Lawson RK, editors. Prostate diseases. Philadelphia (PA): Saunders; 1993. p. 57-71.
5. Waterman MR, Keeney DS. Genes involved in androgen biosynthesis and the male phenotype. Horm Res 1992;38:217-221 (Pubitemid 23185843)
6. Van Den Akker EL, Koper JW, Boehmer AL, et al. Differential inhibition of 17α-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab 2002;87:5714-5721 (Pubitemid 36034381)
7. Kagimoto M, Winter JS, Kagimoto K, Simpson ER, Waterman MR. Structural characterization of normal and mutant human steroid 17 α-hydroxylase genes: molecular basis of one example of combined 17 α-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 1988;2:564-570 (Pubitemid 18152453)
8. Chung BC, Picado-Leonard J, Haniu M, et al. Cytochrome P450c17 (steroid 17 α-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A 1987;84:407-411 (Pubitemid 17006204)
9. Leman ES, DeMiguel F, Gao AC, Getzenberg RH. Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. J Urol 2003;170:235-240 (Pubitemid 36734469)
10. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:120-126 (Pubitemid 36194001)
11. Setiawan VW, Schumacher FR, Haiman CA, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007;16:2237-2246 (Pubitemid 351196355)
12. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:618-624 (Pubitemid 36899841)
13. Hazuda HP, Comeaux PJ, Stern MP, Haffner SM, Eifler CW, Rosenthal M. A comparison of three indicators for identifying Mexican Americans in epidemiologic research. Methodological findings from the San Antonio Heart Study. Am J Epidemiol 1986;123:96-112.
14. Beuten J, Gelfond JA, Byrne JJ, et al. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis 2008;29:1751-1757
15. Hernandez J, Balic I, Johnson-Pais TL, et al. Association between an estrogen receptor α gene polymorphism and the risk of prostate cancer in black men. J Urol 2006;175:523-527 (Pubitemid 43067344)
16. Torkko KC, van Bokhoven A, Mai P, et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 2008;14:3223-3229
17. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-1731 (Pubitemid 29410551)
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265 (Pubitemid 40202029)
19. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-9445 (Pubitemid 37033947)
20. Breiman L. Random forests. Machine learning 2001;45:5-32. (Pubitemid 32933532)
21. Lou XY, Chen GB, Yan L, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 2007;80:1125-1137 (Pubitemid 47579348)
22. Schug JaOGC. TESS: Transcription element search software on the WWW. Technical report CBIL-TR-1997-1001-v0.0 Computational Biology and Informatics Laboratory School of Medicine. PA: University of Pennsylvania; 1997.
23. Long F, Liu H, Hahn C, Sumazin P, Zhang MQ, Zilberstein A. Genome-wide prediction and analysis of function-specific transcription factor binding sites. In Silico Biol 2004;4:395-410. (Pubitemid 40372378)
24. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 2008;44:928-936
25. Miner MM, Seftel AD. Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? Int J Clin Pract 2007;61:622-632
26. Douglas JA, Zuhlke KA, Beebe-Dimmer J, et al. Identifying susceptibility genes for prostate cancer-a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-β. Cancer Epidemiol Biomarkers Prev 2005;14:2035-2039 (Pubitemid 41161220)
27. Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969-978 (Pubitemid 46910099)
28. Forrest MS, Edwards SM, Houlston R, et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 2005;8:95-102.
29. Cicek MS, Conti DV, Curran A, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004;59:69-76. (Pubitemid 38387844)
30. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007;25:3596-3602 (Pubitemid 47376605)
31. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 2005;23:246-253 (Pubitemid 40961936)
32. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-α reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001;57:199-204. (Pubitemid 32065856)
33. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-766
34. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11A in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005;14:2173-2177
35. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003;89:1524-1529 (Pubitemid 37386610)
36. Margiotti K, Kim E, Pearce CL, Spera E, Novelli G, Reichardt JK. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002;53:65-68 (Pubitemid 34966865)
37. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer 2003;106:375-378 (Pubitemid 36870399)
38. Siemiatycki J, Thomas DC. Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol 1981;10:383-387 (Pubitemid 12164642)
39. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-349 (Pubitemid 19077878)
40. Sobti RC, Gupta L, Singh SK, Seth A, Kaur P, Thakur H. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet 2008;185:78-85.
41. Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, Atchison ML. PU.1 recruits a second nuclear factor to a site important for immunoglobulin κ3′ enhancer activity. Mol Cell Biol 1992;12:368-378
42. Pongubala JM, Van Beveren C, Nagulapalli S, et al. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science 1993;259:1622-1625 (Pubitemid 23114644)
43. Kennedy GC, Rutter WJ. Pur-1, a zinc-finger protein that binds to purine-rich sequences, transactivates an insulin promoter in heterologous cells. Proc Natl Acad Sci U S A 1992;89:11498-11502
44. Plaksin D, Baeuerle PA, Eisenbach L. KBF1 (p50 NF-κB homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells. J Exp Med 1993;177:1651-1662 (Pubitemid 23146132)
45. Hohmann HP, Brockhaus M, Baeuerle PA, Remy R, Kolbeck R, van Loon AP. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-κB. TNFα is not needed for induction of a biological effect via TNF receptors. J Biol Chem 1990;265:22409-22417 (Pubitemid 120014316)
46. Ishii S, Kadonaga JT, Tjian R, Brady JN, Merlino GT, Pastan I. Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science 1986;232:1410-1413 (Pubitemid 16059392)
47. Shannon MF, Gamble JR, Vadas MA. Nuclear proteins interacting with the promoter region of the human granulocyte/macrophage colony-stimulating factor gene. Proc Natl Acad Sci U S A 1988;85:674-678 (Pubitemid 18073900)
48. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992;355:446-449
49. Qian X, Samadani U, Porcella A, Costa RH. Decreased expression of hepatocyte nuclear factor 3 α during the acute-phase response influences transthyretin gene transcription. Mol Cell Biol 1995;15:1364-1376
50. Peers B, Voz ML, Monget P, et al. Regulatory elements controlling pituitary-specific expression of the human prolactin gene. Mol Cell Biol 1990;10:4690-4700 (Pubitemid 20264373)
51. Cai RL. Human CART1, a paired-class homeodomain protein, activates transcription through palindromic binding sites. Biochem Biophys Res Commun 1998;250:305-311 (Pubitemid 28463873)
52. Anderson GM, Freytag SO. Synergistic activation of a human promoter in vivo by transcription factor Sp1. Mol Cell Biol 1991;11:1935-1943 (Pubitemid 21895562)
53. Pascal E, Tjian R. Different activation domains of Sp1 govern formation of multimers and mediate transcriptional synergism. Genes Dev 1991;5:1646-1656 (Pubitemid 21906069)
54. Lee JS, Galvin KM, Shi Y. Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc Natl Acad Sci U S A 1993;90:6145-6149 (Pubitemid 23191471)
55. Kataoka H, Joh T, Miura Y, et al. AT motif binding factor 1-A (ATBF1-A) negatively regulates transcription of the aminopeptidase N gene in the crypt-villus axis of small intestine. Biochem Biophys Res Commun 2000;267:91-95 (Pubitemid 30072513)
56. Quong MW, Massari ME, Zwart R, Murre C. A new transcriptional-activation motif restricted to a class of helix-loop-helix proteins is functionally conserved in both yeast and mammalian cells. Mol Cell Biol 1993;13:792-800. (Pubitemid 23040244)
57. Aoki M, Hecht A, Kruse U, Kemler R, Vogt PK. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci U S A 1999;96:139-144 (Pubitemid 29036066)